BridgeMD
New treatment option for Age-Related Macular Degeneration
Official title Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
ClinicalTrials.gov ID: NCT05465252
What this study is testing
- What it's testing
- This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD). Participants will receive 4 capsules of krill oil or placebo daily for a period of 3 months.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 85
You may be able to join if
- Adults diagnosed with dry AMD at an early or intermediate stage, classified according to the Beckman Classification and confirmed by fundus...
- Willing to stop supplementation of omega-3 fatty acids, choline, or astaxanthin.
- Willing to sign the informed consent, and willing to attend follow-up visits for at least 3 months.
You likely can't join if
- Any eye with disease that would interfere with the fundus examinations.
- Eye with choroidal neovascularization (CNV), geographic atrophy (GA), or high myopia.
- Surgeries that may interfere with AMD evaluation.
- Long-term use of any medications that are associated with retinal or neural toxicities.
- History of supplementation with lutein, zeaxanthin, DHA, or EPA, unless a wash-out period of at least 8 weeks is completed prior to enrollment.
- Intraocular pressure more than 26 mmHg.
See the full eligibility criteria
- Adults diagnosed with dry AMD at an early or intermediate stage, classified according to the Beckman Classification and confirmed by fundus photography: (1) Early AMD: medium drusen (\>63 μm and ≤125 μm) without...
- Willing to stop supplementation of omega-3 fatty acids, choline, or astaxanthin.
- Willing to sign the informed consent, and willing to attend follow-up visits for at least 3 months.
- Any eye with disease that would interfere with the fundus examinations.
- Eye with choroidal neovascularization (CNV), geographic atrophy (GA), or high myopia.
- Surgeries that may interfere with AMD evaluation.
- Long-term use of any medications that are associated with retinal or neural toxicities.
- History of supplementation with lutein, zeaxanthin, DHA, or EPA, unless a wash-out period of at least 8 weeks is completed prior to enrollment.
- Intraocular pressure more than 26 mmHg.
- Received cataract surgery in 3 months.
- Other conditions: people with severe systemic diseases; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the...
- Other conditions not suitable for the current study.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.